Published in Dialogues Clin Neurosci on January 01, 2009
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One (2012) 1.51
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol (2009) 1.12
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs (2012) 1.05
Deciphering post-translational modification codes. FEBS Lett (2013) 0.99
Biomarkers in Alzheimer's disease: past, present and future. Biomark Med (2010) 0.93
Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. Eur Arch Psychiatry Clin Neurosci (2012) 0.93
Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer's disease. PLoS One (2012) 0.78
A default mode of brain function. Proc Natl Acad Sci U S A (2001) 50.73
The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A (2005) 37.57
Voxel-based morphometry--the methods. Neuroimage (2000) 34.79
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A (2004) 19.84
Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med (1993) 15.51
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Surrogate end points in clinical trials: are we being misled? Ann Intern Med (1996) 9.81
Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed (2000) 8.18
Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (1992) 7.16
Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron (2006) 6.51
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 5.12
Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging (1998) 5.05
Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol (2006) 4.77
Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci (2006) 4.14
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
The FDA critical path initiative and its influence on new drug development. Annu Rev Med (2008) 4.08
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology (1998) 3.90
In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage (2001) 3.87
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology (2000) 3.84
Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage (2006) 3.77
Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology (2007) 3.71
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci (2001) 3.35
Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. J Magn Reson Imaging (2002) 3.34
Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport (2002) 3.31
Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage (2005) 3.28
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci (2003) 2.63
Differential aging of the medial temporal lobe: a study of a five-year change. Neurology (2004) 2.61
Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging (2004) 2.49
Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology (2003) 2.44
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology (2000) 2.26
Biomarkers and surrogate markers: an FDA perspective. NeuroRx (2004) 2.20
Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging (2006) 2.09
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. Brain (2001) 2.05
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging (2006) 1.91
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.89
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci (2006) 1.85
A voxel based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry (2005) 1.79
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer's disease. Neurobiol Aging (2002) 1.65
Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. Brain (2006) 1.62
White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology (2007) 1.61
Magnetic resonance spectroscopy in AD. Neurology (2001) 1.59
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
A new method for the in vivo volumetric measurement of the human hippocampus with high neuroanatomical accuracy. Hippocampus (2000) 1.56
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
Parahippocampal volume deficits in subjects with aging-associated cognitive decline. Am J Psychiatry (2003) 1.52
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain (2004) 1.45
Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry (1998) 1.44
Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett (2001) 1.44
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Investigating the neural basis for functional and effective connectivity. Application to fMRI. Philos Trans R Soc Lond B Biol Sci (2005) 1.40
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 1.38
Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol (2007) 1.30
Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry (2005) 1.29
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res (2006) 1.28
Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study. Biol Psychiatry (2000) 1.26
Plasma Abeta in Alzheimer's disease--up or down? Lancet Neurol (2006) 1.24
High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun (1999) 1.23
Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. Proc Natl Acad Sci U S A (1990) 1.22
(1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport (2001) 1.19
Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord (2002) 1.16
Biochemistry and molecular biology of tauopathies. Neuropathology (2006) 1.14
Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down's syndrome brains. Lab Invest (1989) 1.13
Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging (2007) 1.12
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett (2006) 1.11
A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord (2002) 1.10
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging (2007) 1.10
Multicenter assessment of reliability of cranial MRI. Neurobiol Aging (2005) 1.08
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol (2001) 1.08
Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology (2002) 1.08
Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. J Neurol (2006) 1.07
Imaging Alzheimer's disease: clinical applications. Neuroimaging Clin N Am (2003) 1.06
Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan. Neurobiol Aging (2006) 1.06
Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer's disease: a diffusion tensor imaging and voxel-based morphometry study. Cereb Cortex (2006) 1.05
Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet (2006) 1.04
Mild cognitive impairment. Lancet (2006) 10.21
Burnout: a fashionable diagnosis. Dtsch Arztebl Int (2011) 4.64
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry (2009) 1.54
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol (2006) 1.29
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry (2010) 1.27
Hippocampal volume and 2-year outcome in depression. Br J Psychiatry (2008) 1.24
Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. Am J Psychiatry (2005) 1.19
Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci (2014) 1.18
Reduced cerebellar volume and neurological soft signs in first-episode schizophrenia. Psychiatry Res (2005) 1.14
Interhemispheric hypoconnectivity in schizophrenia: fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. Neuroimage (2011) 1.10
Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach. Psychiatry Res (2005) 1.09
Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol. J Alzheimers Dis (2011) 1.08
Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord (2009) 1.08
Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett (2002) 1.06
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna) (2011) 1.04
Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res (2003) 1.03
Anticholinergic drug use and risk for dementia: target for dementia prevention. Eur Arch Psychiatry Clin Neurosci (2010) 1.03
Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci (2003) 1.03
Different patterns of white matter degeneration using multiple diffusion indices and volumetric data in mild cognitive impairment and Alzheimer patients. PLoS One (2012) 1.01
Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. Mol Neurobiol (2012) 0.99
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry (2010) 0.98
Structural changes of the corpus callosum in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord (2006) 0.98
Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci (2010) 0.96
Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Res (2010) 0.95
Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol Psychiatry (2009) 0.94
Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother (2014) 0.92
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy. Psychiatry Res (2009) 0.92
Hippocampal volume in first episode and recurrent depression. Psychiatry Res (2009) 0.92
Comparison of manual direct and automated indirect measurement of hippocampus using magnetic resonance imaging. Eur J Radiol (2007) 0.91
Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice. Neuropsychiatr Dis Treat (2010) 0.91
TANDEM: Communication training for informal caregivers of people with dementia. Aging Ment Health (2011) 0.90
Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´s Disease. Curr Neuropharmacol (2013) 0.84
Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. J Alzheimers Dis (2009) 0.84
Life events and hippocampal volume in first-episode major depression. J Affect Disord (2008) 0.84
Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci (2009) 0.83
Left anterior temporal lobe sustains naming in Alzheimer's dementia and mild cognitive impairment. Curr Alzheimer Res (2011) 0.82
Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci (2005) 0.81
Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia. Neurosci Lett (2007) 0.80
Galantamine for Alzheimer's disease. Expert Opin Drug Metab Toxicol (2010) 0.80
Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett (2003) 0.80
Cerebrospinal fluid tau protein levels in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2003) 0.80
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects. Thromb Haemost (2006) 0.79
Association of microstructural white matter abnormalities with cognitive dysfunction in geriatric patients with major depression. Psychiatry Res (2012) 0.79
APOE-dependent phenotypes in subjects with mild cognitive impairment converting to Alzheimer's disease. J Alzheimers Dis (2013) 0.78
Voltage-gated Ca(2+) channel mediated Ca(2+) influx in epileptogenesis. Adv Exp Med Biol (2012) 0.78
Anticonvulsants in the treatment of aggression in the demented elderly: an update. Clin Pract Epidemiol Ment Health (2009) 0.78
Visual perceptual organization deficits in Alzheimer's dementia. Dement Geriatr Cogn Disord (2008) 0.78
Verbal episodic memory deficits in remitted bipolar patients: a combined behavioural and fMRI study. J Affect Disord (2013) 0.78
Episodic memory impairments in bipolar disorder are associated with functional and structural brain changes. Bipolar Disord (2014) 0.78
Diagnostic accuracy of the clock drawing test: the relevance of "time setting'' in screening for dementia. J Geriatr Psychiatry Neurol (2008) 0.77
Recognition memory is associated with altered resting-state functional connectivity in people at genetic risk for Alzheimer's disease. Eur J Neurosci (2014) 0.77
Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index. Dement Geriatr Cogn Disord (2005) 0.77
Cognitive intervention response is related to habitual physical activity in older adults. Aging Clin Exp Res (2011) 0.77
Neurocognitive Deficits and Effects of Cognitive Reserve in Mild Cognitive Impairment. Dement Geriatr Cogn Disord (2016) 0.76
DSM-5 and clinical trials in psychiatry: challenges to come? Nat Rev Drug Discov (2012) 0.76
Physical Exercise for the Treatment of Neuropsychiatric Disturbances in Alzheimer's Dementia: Possible Mechanisms, Current Evidence and Future Directions. Curr Alzheimer Res (2016) 0.75
[CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease]. Z Gerontol Geriatr (2008) 0.75
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency]. Z Evid Fortbild Qual Gesundhwes (2013) 0.75
Need for and challenges facing functional communication as outcome parameter in AD clinical trials. Alzheimer Dis Assoc Disord (2013) 0.75
Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review. Curr Alzheimer Res (2017) 0.75
[Addiction in Old Age]. Dtsch Med Wochenschr (2017) 0.75
[Non-pharmacological interventions in dementia: an overview with special consideration of digital offerings]. Dtsch Med Wochenschr (2022) 0.75
Neural correlates of autobiographical memory in amnestic Mild Cognitive Impairment. Psychiatry Res (2012) 0.75
Neuropsychiatric Disturbances in Mild Cognitive Impairment (MCI): A Systematic Review of Population-Based Studies. Curr Alzheimer Res (2016) 0.75
Lifespan Leisure Physical Activity Relates To Brain Metabolism In Old Age: 3870 Board #309 June 4, 9: 30 AM - 11: 00 AM. Med Sci Sports Exerc (2016) 0.75